Cargando…
CSP I-plus modified rEndostatin inhibits hepatocellular carcinoma metastasis via down-regulation of VEGFA and integrinβ1
BACKGROUND: In our previous study, N end of the Circumsporozoite protein (CSP I-plus) modified recombinant human Endostatin (rEndostatin, endostar) (rES-CSP) was constructed, which had antiangiogenic capability and bound to hepatocellular carcinoma in vivo and in vitro. In this study, the inhibition...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682839/ https://www.ncbi.nlm.nih.gov/pubmed/36419008 http://dx.doi.org/10.1186/s12885-022-10318-8 |
_version_ | 1784834944298647552 |
---|---|
author | Chen, Xueqin Wang, Yan Liu, Hancong Zhang, Jingjing Wang, Jie Jin, Xiaobao Ma, Yan |
author_facet | Chen, Xueqin Wang, Yan Liu, Hancong Zhang, Jingjing Wang, Jie Jin, Xiaobao Ma, Yan |
author_sort | Chen, Xueqin |
collection | PubMed |
description | BACKGROUND: In our previous study, N end of the Circumsporozoite protein (CSP I-plus) modified recombinant human Endostatin (rEndostatin, endostar) (rES-CSP) was constructed, which had antiangiogenic capability and bound to hepatocellular carcinoma in vivo and in vitro. In this study, the inhibition of rES-CSP on hepatocellular carcinoma metastasis was verified in vivo and in vitro, and its possible mechanism was explored. METHODS: Firstly, the impact of rES-CSP on the migration, adhesion of hepatoma cell HCCLM3 was identified by wound healing, transwell, and on metastasis of orthotopic xenograft model was identified in nude mouse. Then the expression of metastasis-associated molecules (MMP2, E-cadherin, integrinβ1) and angiogenesis-related factors (VEGFA) in vitro and in vivo were detected by real-time PCR, western blotting, immunohistochemistry. RESULTS: Finally, we found that rES-CSP could inhibit the migration and invasion of HCCLM3, and decrease tumor metastasis and growth in nude mouse orthotopic xenograft models. The tumor inhibiting rates of rES-CSP and Endostar were 42.46 ± 5.39% and 11.1 ± 1.88%. The lung metastasis rates of the control, Endostar and rES-CSP were 71, 50, and 42.8%, respectively. Compared with Endostar, rES-CSP significantly down-regulated the expression of VEGFA and integrinβ1. Heparin, a competitive inhibitor of CSP I-plus, which can be bind to the highly-sulfated heparan sulfate proteoglycans (HSPGs) over-expressed in liver and hepatocellular carcinoma, alleviated the down-regulation of VEGFA and integrinβ1. CONCLUSIONS: These indicate that rES-CSP may play a role in inhibiting tumor growth and metastasis by down-regulating the angiogenic factor VEGF and the metastasis-related molecules or by interfering with HSPGs-mediated tumor metastasis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-10318-8. |
format | Online Article Text |
id | pubmed-9682839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-96828392022-11-24 CSP I-plus modified rEndostatin inhibits hepatocellular carcinoma metastasis via down-regulation of VEGFA and integrinβ1 Chen, Xueqin Wang, Yan Liu, Hancong Zhang, Jingjing Wang, Jie Jin, Xiaobao Ma, Yan BMC Cancer Research BACKGROUND: In our previous study, N end of the Circumsporozoite protein (CSP I-plus) modified recombinant human Endostatin (rEndostatin, endostar) (rES-CSP) was constructed, which had antiangiogenic capability and bound to hepatocellular carcinoma in vivo and in vitro. In this study, the inhibition of rES-CSP on hepatocellular carcinoma metastasis was verified in vivo and in vitro, and its possible mechanism was explored. METHODS: Firstly, the impact of rES-CSP on the migration, adhesion of hepatoma cell HCCLM3 was identified by wound healing, transwell, and on metastasis of orthotopic xenograft model was identified in nude mouse. Then the expression of metastasis-associated molecules (MMP2, E-cadherin, integrinβ1) and angiogenesis-related factors (VEGFA) in vitro and in vivo were detected by real-time PCR, western blotting, immunohistochemistry. RESULTS: Finally, we found that rES-CSP could inhibit the migration and invasion of HCCLM3, and decrease tumor metastasis and growth in nude mouse orthotopic xenograft models. The tumor inhibiting rates of rES-CSP and Endostar were 42.46 ± 5.39% and 11.1 ± 1.88%. The lung metastasis rates of the control, Endostar and rES-CSP were 71, 50, and 42.8%, respectively. Compared with Endostar, rES-CSP significantly down-regulated the expression of VEGFA and integrinβ1. Heparin, a competitive inhibitor of CSP I-plus, which can be bind to the highly-sulfated heparan sulfate proteoglycans (HSPGs) over-expressed in liver and hepatocellular carcinoma, alleviated the down-regulation of VEGFA and integrinβ1. CONCLUSIONS: These indicate that rES-CSP may play a role in inhibiting tumor growth and metastasis by down-regulating the angiogenic factor VEGF and the metastasis-related molecules or by interfering with HSPGs-mediated tumor metastasis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-10318-8. BioMed Central 2022-11-22 /pmc/articles/PMC9682839/ /pubmed/36419008 http://dx.doi.org/10.1186/s12885-022-10318-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Chen, Xueqin Wang, Yan Liu, Hancong Zhang, Jingjing Wang, Jie Jin, Xiaobao Ma, Yan CSP I-plus modified rEndostatin inhibits hepatocellular carcinoma metastasis via down-regulation of VEGFA and integrinβ1 |
title | CSP I-plus modified rEndostatin inhibits hepatocellular carcinoma metastasis via down-regulation of VEGFA and integrinβ1 |
title_full | CSP I-plus modified rEndostatin inhibits hepatocellular carcinoma metastasis via down-regulation of VEGFA and integrinβ1 |
title_fullStr | CSP I-plus modified rEndostatin inhibits hepatocellular carcinoma metastasis via down-regulation of VEGFA and integrinβ1 |
title_full_unstemmed | CSP I-plus modified rEndostatin inhibits hepatocellular carcinoma metastasis via down-regulation of VEGFA and integrinβ1 |
title_short | CSP I-plus modified rEndostatin inhibits hepatocellular carcinoma metastasis via down-regulation of VEGFA and integrinβ1 |
title_sort | csp i-plus modified rendostatin inhibits hepatocellular carcinoma metastasis via down-regulation of vegfa and integrinβ1 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682839/ https://www.ncbi.nlm.nih.gov/pubmed/36419008 http://dx.doi.org/10.1186/s12885-022-10318-8 |
work_keys_str_mv | AT chenxueqin cspiplusmodifiedrendostatininhibitshepatocellularcarcinomametastasisviadownregulationofvegfaandintegrinb1 AT wangyan cspiplusmodifiedrendostatininhibitshepatocellularcarcinomametastasisviadownregulationofvegfaandintegrinb1 AT liuhancong cspiplusmodifiedrendostatininhibitshepatocellularcarcinomametastasisviadownregulationofvegfaandintegrinb1 AT zhangjingjing cspiplusmodifiedrendostatininhibitshepatocellularcarcinomametastasisviadownregulationofvegfaandintegrinb1 AT wangjie cspiplusmodifiedrendostatininhibitshepatocellularcarcinomametastasisviadownregulationofvegfaandintegrinb1 AT jinxiaobao cspiplusmodifiedrendostatininhibitshepatocellularcarcinomametastasisviadownregulationofvegfaandintegrinb1 AT mayan cspiplusmodifiedrendostatininhibitshepatocellularcarcinomametastasisviadownregulationofvegfaandintegrinb1 |